E-Doc: Medicine Info For Urofollitrophin (FSH) A high level of gonadotrophins indicating primary ovarian failure. Primary ovarianfailure should be excluded by determination of serum FSH and LH. http://www.edoc.co.za/medilink/actives/1072.html
Extractions: FSH when given with LH may cause sensitivity reactions and dose related ovarian hyperstimulation varying from mild ovarian enlargement and abnormal discomfort to severe hyperstimulation with ovarian rupture and intraperitoneal haemorrhage. There may be ascites, pleural effusion, oliguria, hypotension, arterial thrombo-embolism. Swelling of pre-existing pituitory tumours leading to visual field defects may occur during pregnancy in women treated for infertility. There is a risk of multiple births.
Causes Of And Diagnostic Approach To Primary Amenorrhea and perhaps other hormones. A high serum FSH concentration is indicativeof primary ovarian failure. A karyotype is then required http://www.uptodate.com/patient_info/topicpages/topics/R_Endo_F/17023.asp
Extractions: Amenorrhea (absence of menses) can be a transient, intermittent, or permanent condition resulting from dysfunction of the hypothalamus, pituitary, ovaries, uterus, or vagina ( show table 1 and show table 2 ). It is often classified as either primary (absence of menarche by age 16) or secondary (absence of menses for more than three cycle intervals or six months in women who were previously menstruating). The menstrual cycle is susceptible to outside influences; thus, missing a single menstrual period is rarely important. In contrast, prolonged amenorrhea might be the earliest sign of a decline in general health or signal an underlying condition, such as a pituitary tumor.
Korean Standard Classification Of Diseases drug, if druginduced E28.2 Polycystic ovarian syndrome Sclerocystic ovary syndromeStein-Leventhal syndrome E28.3 primary ovarian failure Decreased estrogen http://www.nso.go.kr/eng/standards/edis/e28.htm
Extractions: E28 Ovarian dysfunction Exclusion : isolated gonadotropin deficiency(E23.0) postprocedural ovarian failure(E89.4) E28.0 Estrogen excess Use additional external cause code(Chapter XX), if desired, to identify drug, if drug-induced E28.1 Androgen excess Hypersecretion of overian androgens Use additional external cause code(Chapter XX), if desired, to identify drug, if drug-induced E28.2 Polycystic ovarian syndrome Sclerocystic ovary syndrome Stein-Leventhal syndrome E28.3 Primary ovarian failure Decreased estrogen Premature menopause NOS Resistant ovary syndrome Exclusion : menopausal and female climacteric states(N95.1) pure gonadal dysgenesis(Q99.1) Turner's syndrome(Q96.-) E28.8 Other ovarian dysfunction Ovarian hyperfunction NOS E28.9 Ovarian dysfunction, unspecified
CCOP fertility treatment (except Clomiphen or Pergonal; a history of ovariandysfunction. known family history of primary ovarian failure. http://ccop.moffitt.usf.edu/Guest/Triptorelin.html
Extractions: Premenopausal women (defined as baseline FSH level less than 40). at or under the age of 44 years. who have had at least 2 periods in the last 6 months . are scheduled to receive neo- or adjuvant chemotherapy after surgery for node negative primary breast cancer. Patients may undergo either mastectomy (post-op RT optional) or breast-conserving surgery (post-op RT required). Oral contraceptives may not have been taken within at least two weeks of study entry.
RxMed: Pharmaceutical Information - HUMEGON of ovulation and pregnancy in females infertile due to anovulation where thecause of anovulation is functional and not due to primary ovarian failure. http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS- Monographs/CP
Extractions: HUMEGON® Organon Human Gonadotropin Human Gonadotropins Action And Clinical Pharmacology: Humegon (human gonadotropin) is a purified preparation of gonadotropins extracted from the urine of post menopausal and pregnant women. It contains follicle-stimulating hormone (FSH) and luteinizing hormone (LH), both of which are necessary for the normal gamete maturation (follicle ripening in the female and spermatogenesis in the male) and for gonadal steroid production. Unlike menotropins, human gonadotropin is standardized with hCG. Human gonadotropin is used to stimulate these processes in selected cases of disturbed gonadal function. It is generally used in combination with a gonadotropin with LH activity, such as human chorionic gonadotropin (hCG). The combined treatment may be either sequential (in the case of ovulation induction) or concomitant (in the case of Leydig cell stimulation). tag_IndicationsIndications
MEDLINEplus Drug Information: Follitropin Alfa (Systemic) primary ovarian failureFollitropin alfa will not work in patientswhose ovaries no longer develop eggs. Proper Use of This Medicine. http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/203454.html
Extractions: Other drug names: A-Am An-Az B C-Ch ... W-Z Contents of this page: Follitropin alfa (fol-li-TROE-pin AL-fa) is a hormone identical to follicle-stimulating hormone (FSH) produced by the pituitary gland. FSH helps to develop eggs in the ovaries. Follitropin alfa is used as a fertility medicine to develop eggs in women who have not been able to become pregnant because of problems in ovulation. Also, many women wanting to become pregnant will use this medicine while enrolled in a fertility program (assisted reproductive technology [ART]) that uses procedures such as in vitro fertilization (IVF) or embryo transfer (ET). Follitropin alfa may be used with other medicines for these purposes. Follitropin alfa is also used as a fertility medicine to help men with low sperm counts produce more sperms. Treatment with human chorionic gonadotropin should come before treatment with follitropin alfa. This pretreatment elevates the amount of testosterone to the correct level. Treatment with human chorionic gonadotropin should continue as long as follitropin alfa is being used. Some patients may be treated with another hormone called gonadotropin-releasing hormone agonist (GnRHa) before starting treatment with follitropin alfa. GnRHa reduces the amount of FSH released from the pituitary gland. This is done so that the doctor can replace their FSH with follitropin alfa in the proper amounts each day to achieve fertility.
Clinic Conference In premature primary ovarian failure, estrogen hormone replacement therapy is indicated,with progestin added for women who have an uterus in order to protect http://www.intmed.mcw.edu/ClinicConf/03-11-02 res Amenorrhea.htm
Extractions: Marilyn M. Schapira, MD, MPH AMENORRHEA Clinic Conference: March 11-15, 2002 Resident Version The materials for this conference include a handbook chapter written by Dr. Schapira and two journal articles on the topic: Crosignani G; Vegetti W. A Practical Guide to the Diagnosis and Management of Amenorrhoea. Drugs 1996 Nov. 52(5) p671- 81. Warren MP. Clinical Review 77: Evaluation of Secondary Amenorrhea. (http://home.mdconsult.com/das/search/query/17057242 Teaching Points The definition of secondary amenorrhea is the absence of menses for at least 3 months in a women who has previously had her menarche. The prevalence in the general population is 2-5%. Hyperprolactinemia amenorrhea is one cause of secondary amenorrhea. Drugs that cause hyperprolactinemia include estrogens, androgens, anxiolytics, narcotics, methyldopa, reserpine, amphetamines, and H2 blockers. Prolactin should be measured in the morning in a fasting state. A normal level is 20-25 ug/L. A relatively common cause of amenorrhea in young women is an acquired form of hypogonadotrophic amenorrhea due to emotional distress, nutritional deficiency, or athletic activity. The female athletic triad is defined as the combined conditions of disordered eating, amenorrhea, and osteoporosis that occurs in female athletes. Physiologic causes of secondary amenorrhea include pregnancy and menopause.
Extractions: 1. Tanner, J.M. and R.H. Whitehouse, Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child, 1976. 51(3): p. 170-9. 2. Marshall, W.A. and J.M. Tanner, Variations in pattern of pubertal changes in girls. Arch Dis Child, 1969. 44(235): p. 291-303. 3. Herman-Giddens, M.E., et al., Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics, 1997. 99(4): p. 505-12. 4. Kosho, T., et al., Skeletal features and growth patterns in 14 patients with haploinsufficiency of SHOX: implications for the development of Turner syndrome. J Clin Endocrinol Metab, 1999. 84(12): p. 4613-21. 5. Rao, E., et al., Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet, 1997. 16(1): p. 54-63. 6. Clement-Jones, M., et al., The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet, 2000. 9(5): p. 695-702. 7. Lee, M., Growth hormone deficiency as the only identifiable cause for primary amenorrhea. J Pediatr Adolesc Gynecol, 2000. 13(2): p. 93.
Drug Database | Building Better Health Genital Syphilis Primary Hypogonadism due to Bilateral Torsion Primary Hypogonadismdue to Orchitis primary ovarian failure Primary Prevention http://www.buildingbetterhealth.com/conditionlist/p
Extractions: The information in this database is intended to supplement, not substitute for, the expertise and judgment of your healthcare professional. The information is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate, or effective for you. You should consult your healthcare professional before taking any drug, changing your diet, or commencing or discontinuing any course of treatment. Home Women's Health Men's Health Senior Health ... Drugstore AdvancePCS makes this Web site available free to users for the sole purposes of providing educational information on health-related issues and providing access to health-related resources. This Web site's health-related information and resources are not intended to be a substitute for professional medical advice or for the care that patients receive from their physicians. Please review the We subscribe to the HONcode principles of the Health On the Net Foundation Home Contact Us About Building ... AdvancePCS.com
ICD-9-CM From Code 250 primary ovarian failure. 256.4 Polycystic ovaries Isosexual virilizationSteinLeventhal syndrome. 256.8 Other ovarian dysfunction; http://www.cpmc.columbia.edu/homepages/hripcsa/icd9/1tabular250.html
POF Premature ovarian failure as with many conditions develops over time. differentstages through what's now called primary ovarian insufficiency (POI),. http://www.earlymenopause.com/POF.htm
Extractions: Fact Sheet: Premature Ovarian Failure (POF) A Brief Look at POF As has been said elswhere on the site, premature ovarian failure (POF) is a condition that used to be called "premature menopause." It's marked by post-menopausal hormone levels and no periods (amenorrhea) ocurring before the age of 40. While it's similar to menopause, it's not strictly menopause. There are several key differences. One of the most important differences is that many women with POF can and do still ovulate from time to time and can even get pregnant. (According to statistics, this occurs to roughly 8 to 10% of women with POF.) This is because POF doesn't necessarily mean lack of viable follicles. Yes, some women with POF do have early depletion of follicles (which is then, in effect, menopause). But others nearly half according to some experts actually still have follicles. The problem in this case is a "disconnect" between hormones and ovarian function or an autoimmune problem. Premature ovarian failure as with many conditions develops over time. Prior to full-blown POF (i.e. no periods for at least 4-6 months and post-menopausal hormone levels), you move through different stages through what's now called "primary ovarian insufficiency" (POI)
FSH: The Test In women, FSH and LH levels can help to differentiate between primary ovarianfailure (failure of the ovaries themselves) and secondary ovarian failure http://www.labtestsonline.org/understanding/analytes/fsh/test.html
Extractions: TESTS test not listed? ACTH AFB Culture AFP Maternal AFP Tumor Marker Albumin Aldosterone Allergies ALP ALT Amylase ANA Antibody Tests Apo A Apo B ApoE Genotyping AST Bilirubin Blood Culture Blood Gases BMP BNP Bone Markers BRCA BUN C-peptide CA-125 CA 15-3 CA 19-9 Calcium Cardiac Risk CBC CEA CF Gene Mutation Chlamydia Chloride Cholesterol CK CK-MB CMP Cortisol Creatinine Creatinine Clearance CRP CRP, high-sensitivity Cystatin C DHEAS Differential EGFR Electrolytes ESR Estrogen Estrogen Receptors Fecal Occult Blood Ferritin Flu Tests FSH Genotypic Resistance GFR GGT Glucose Gonorrhea Gram Stain Growth Hormone hCG HDL Hematocrit Hemoglobin Hepatitis A Hepatitis B Hepatitis C Her-2/neu Herpes HIV Antibody Home Tests Homocysteine HPV H-pylori hs-CRP Insulin Iron Tests LD LDH LDL Lead LH Lipase Lipid Profile Liver Panel Lp(a) Lyme Disease Magnesium Microalbumin Mono Monoclonal Protein Myoglobin Pap Smear Phosphorus Platelets Potassium Prealbumin Progesterone Progest. Receptors Prolactin PSA PT PTH Red Count Renin Rheumatoid Factor Rubella Semen Analysis Serum Iron Sickle Cell Sodium Strep Throat Sweat Chloride Syphilis Tau/Aß42 TB Skin Test Testosterone Ther. Drug Monitoring
Extractions: Little is known about the causes of Premature Ovarian Failure (POF) in women. This disorder is defined as the loss of ovarian function before the age of forty. It is clinically characterized by secondary amenorrhea and endocrinologically by a hypergonadotropic, hypoestrogenic state. Unfortunately, a definite etiological factor can not be determined for most cases (van Kasteren, 1999). Currently, the condition is divided into two classes: excessive depletion of follicles and follicles that are present but fail to function properly. It is also likely that different classes POF exist due to different causes or varying levels of the agents responsible for this disorder. It is possible that one of the major or contributing causes of POF dysfunction involves the autoimmune reaction against the oocyte and/or other components of the follicle. Such a primary relationship might follow an initial abnormal exposure of zona material to the immune system. Alternatively, in POF or other types of pathology, anti zona pellucida antibodies (aZP) might form as a secondary consequence of disease conditions (Shivers and Dunbar, 1977).
Extractions: III. Department of Medicine, University of Leipzig, Leipzig, Germany Download the FULL TEXT of this article in Acrobat PDF format. If you have not previously downloaded PDF files we suggest you access our Advice page for further information. European Journal of Endocrinology Return to the Contents List - Vol. 146 Part 1
Extractions: (advertisement) Home Specialties CME PDA ... Patient Education Articles Images CME Patient Education Advanced Search Link to this site Back to: eMedicine Specialties Medicine, Ob/Gyn, Psychiatry, and Surgery Obstetrics/gynecology Last Updated: November 29, 2001 Rate this Article Email to a Colleague Synonyms and related keywords: premature ovarian failure, primary ovarian failure, premature menopause, primary ovarian insufficiency, POF AUTHOR INFORMATION Section 1 of 10 Author Information Introduction Clinical Differentials ... Bibliography Author: Vladimir Bakalov, MD , Clinical Associate, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health Coauthor(s): Lawrence M Nelson, MD, MBA , Head of Gynecologic Endocrinology Unit, Investigator, Section of Women's Health Research, Developmental Endocrinology Branch, National Institutes of Health Vladimir Bakalov, MD, is a member of the following medical societies: Endocrine Society Editor(s): Thomas Michael Price, MD
Infertility - A Couple's Survival Guide In one study, women with gonadal (ovarian) failure and primary amenorrhea were consistentlyfound to have no follicular activity on pathology reports (of the http://www.drdaiter.com/47.html
Extractions: Premature Ovarian Failure Ovarian failure results when there are no eggs available for maturation. With ovarian failure the fertility prognosis is poor unless donor eggs are used. The FSH concentration (ideally with LH and estradiol concentrations) can confirm ovarian failure. In one study, women with gonadal (ovarian) failure and primary amenorrhea were consistently found to have no follicular activity on pathology reports (of the ovarian tissue) when the FSH concentration was greater than 40 IU/L. These data may not be entirely applicable to ovarian failure with secondary amenorrhea, but consistently elevated FSH concentrations (usually greater than 25 IU/L and certainly greater than 40 IU/L) with a coincident low estradiol concentration (to rule out a FSH producing pituitary tumor) and secondary amenorrhea strongly suggests ovarian failure. Menopause is the absence of menstruation due to the depletion of eggs capable of maturation. The average age of menopause in the USA is about 51-52 years old. Less than 1% of women have "menopause" when younger than 40 years old, so that when this occurs it is called "premature ovarian failure" or POF. There appear to be two main causes of this accelerated loss of eggs such that there is total depletion of maturation capable eggs at a very young age (POF). First, there may be a chromosomal abnormality in the X chromosome affecting the genes that regulate the rate of egg loss. Second, autoimmune disease that produces antibodies that can attack and destroy the ovaries is able to result in early ovarian failure.
Colorado Reproductive Endocrinology Presentation of the Woman With Premature ovarian failure The age at which POF occursmay depend upon the It may present as primary or secondary amenorrhea. http://www.coloradofertility.com/physician_prem_failure2.htm
Extractions: The age at which POF occurs may depend upon the number of follicles initially present and the pace of follicular atresia. It may present as primary or secondary amenorrhea. Women with primary amenorrhea are more likely to have a genetic basis for the POF, having had a smaller complement of oocytes initially. About half of women with POF have a history of infrequent or irregular menses, while about one fourth stop menstruating suddenly. Often these women also have a recent history of infertility. Although those women with primary amenorrhea have no symptoms related to low estradiol levels, the majority of those with secondary amenorrhea typically present with the complaints of hot flashes, fatigue, and mood changes. Theses symptoms may start before the complete cessation of menses. Women with primary amenorrhea may present with signs of Turner's syndrome, while those with secondary amenorrhea usually have normal physical findings. At least one third of women with POF have ovarian follicles visible on ultrasound and many have estradiol levels over 50 pg/ml. Almost 20% may occasionally ovulate. A recent study showed no relationship between the risk of POF and age at menarche, cycle length, and oral contraceptive use. Parity was related to a decreased risk of POF and those women with POF were more likely to have a history of infertility.
